Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Business News › Canaccord Genuity Initiates Coverage of Natera With Buy Rating

Canaccord Genuity Initiates Coverage of Natera With Buy Rating

Jan 06, 2017
|
staff reporter

NEW YORK (GenomeWeb) – Canaccord Genuity today initiated coverage of molecular diagnostics company Natera with a Buy rating. It set a price target of $18.00 for the company's stock.

The San Carlos, California-based company markets a sequencing-based noninvasive prenatal test and is developing cancer products that analyze circulating tumor DNA.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Feb
23
Featured Webinar

After the Surge: Driving Sample Processing Efficiency of Coronavirus Samples

Sponsored by
Thermo Fisher Scientific

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before. 

What's Popular?

In Molecular Diagnostics

  1. Infectious Disease Test Firm Talis Biomedical Files for IPO

  2. NASA Looking to Spin Out Breath Analysis Platform for Use in Diagnostics Applications

    Premium

  3. Fluxergy Aiming to Provide Low-Cost, Multimodal Testing for SARS-CoV-2, Other Disease Targets

    Premium

  4. President Biden Announces Plan to Expand SARS-CoV-2 Testing, Increase Capacity

  5. NeoGenomics to Grow Pharma, Informatics Divisions Through CDx Agreements, Acquisitions

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.